Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Advanced Medicine

Advanced Medicine In Brief

  • Meet what some are calling the world’s largest cell and gene CDMO. The new Center for Breakthrough Medicines facility will claim 680,000 square feet of the Discovery Labs complex, based in the King of Prussia area of Pennsylvania. Through $1.2 billion of funding by MLP Ventures, the new CDMO will employ 2,000 scientists, manufacturing experts, lab technicians, and support staff. The aim? To crack the production capacity problem.
  • In a study that has received widespread media coverage, researchers used genome-wide CRISPR–Cas9 screening to uncover a TCR able to recognize and kill most human cancer types via the monomorphic MHC class I-related protein, MR1, while remaining inert to noncancerous cells. The new TCR was successful in mice and in vitro human cancer models. 
  • Citing Cancer Research Institute figures, a recent review offered insight into the global landscape of CAR-T cell therapy. As of February 2018, there were 404 CAR-Ts in the clinic, with the USA and China accounting for 80 percent of the total with 171 and 152, respectively. In terms of targets, both countries were focused on CD19 (over 40 percent), but in the USA, the second most common target of CAR-T cell clinical trials is BCMA; meanwhile, Chinese researchers are tackling CD20, CD22, and GPC3.

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register